Second Quarter 2024 Business Update & Financial Results Conference Call

Aaron Berg
CEO & President

Tom Reilly
CFO

AMARIN®

July 31, 2024

Forward Looking Statements & Disclaimer

This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, generic product launches, research and development, intellectual property and litigation matters, and other statements and beliefs that are forward-looking in nature and depend upon or refer to future events or conditions, including certain financial initiatives, metrics, and guidance.

These statements involve known and unknown risks, uncertainties and other factors that can cause actual results to differ materially. Investors should not place undue reliance on forward-looking statements, which speak only as of the presentation date of this presentation. Please refer to the "Risk Factors" section in Amarin's most recent Forms 10-K and 10-Q filed with the SEC and cautionary statements outlined in recent press releases for more complete descriptions of risks in an investment in Amarin.

THIS PRESENTATION IS INTENDED FOR COMMUNICATION WITH INVESTORS AND NOT FOR DRUG PROMOTION.

AMARIN, VASCEPA, VAZKEPA and REDUCE-IT are trademarks of Amarin Pharmaceuticals Ireland Limited. VAZKEPA is a registered trademark in Europe and other countries and regions and is pending registration in the United States.

Today's Agenda

01

SECOND QUARTER 2024 BUSINESS UPDATE

Aaron Berg, President & CEO

02

SECOND QUARTER 2024 FINANCIAL RESULTS

Tom Reilly, CFO

03

CLOSING & Q&A

Aaron Berg, President & CEO

01 SECOND QUARTER 2024 BUSINESS UPDATE



Aaron Berg
President & CEO

UNLOCKING THE VALUE OF VASCEPA/VAZKEPA

VASCEPA/VAZKEPA VALUE

- 10+ YEARS OF SCIENCE & CLINICAL DATA
- GLOBAL UNMET NEED TO REDUCE CV RISK
- SIGNIFICANT UNTAPPED MARKET POTENTIAL IN EUROPE & ROW
- EUROPEAN IP PROTECTION INTO 2039

OUR FOCUS:

EVALUATE **EVERY OPPORTUNITY** TO MAXIMIZE THE IMPACT OF VASCEPA/VAZKEPA FOR MILLIONS OF PATIENTS **GLOBALLY**

EUROPE: LEVERAGING THE LONG-TERM VALUE OF VAZKEPA TO ACCELERATE REVENUE AND PRICING & REIMBURSEMENT PROGRESS

REFOCUSED STRATEGY BEGINNING TO DELIVER RESULTS

1. **Targeted Patient & Customer Base at Launch**
   Address urgency to treat.
   Focus on high-risk patients backed up by data and treated by specialists.

2. **Resource Optimisation/Prioritisation**
   Resource allocation on prioritised geographies and implementation of new, efficient operational model.

3. **Enhanced VAZKEPA Value Proposition**
   Country-centric value offering reflecting different payer's needs.

A INCREASE IMPACT – PARTICULARLY FROM EU5

Accelerating Growth & Revenue and Advancing Pricing & Reimbursement

UK | SPAIN
FRANCE | ITALY | GERMANY

B SUPPORT EFFORTS IN REST OF EUROPE

Advancing Pricing & Reimbursement Efforts and Continued Commercialization in Other Markets

AUSTRIA | NORWAY | REPUBLIC OF IRELAND
NETHERLANDS | SWEDEN | PORTUGAL
ISRAEL | GREECE

EUROPEAN IP EXTENSION PROVIDES LONGER RUNWAY TO MAXIMIZE COMMERCIAL OPPORTUNITY AND VALUE FOR VAZKEPA

REST OF WORLD: ADVANCING VASCEPA/VAZKEPA VALUE THROUGH ACCESS & UPTAKE IN KEY PARTNERSHIP MARKETS

20+ REGULATORY PROCESSES UNDERWAY

CANADA
Alberta Product Listing Agreement Announced July '24
HLS Therapeutics Inc.

CHINA
CVRR approval secured; NRDL process ongoing
EDDING PHARM 亿腾

SOUTH KOREA AND ASEAN (LOTUS)
Regulatory processes ongoing; key focus for 2024
Lotus

MENA
Launches continuing in KSA, Kuwait
Biologix FZCO

AUSTRALIA / NEW ZEALAND
Australia P&R process advancing through final stages
CSL Seqirus

- Launched
- Regulatory Approval Achieved; P&R Efforts in Process
- Regulatory Preparations in Process

Note: The company is pursuing expansion into these various additional markets and the status of regulatory and/or patent approval will vary market to market.

U.S.: CONTINUES TO DELIVER CASH AND IPE MARKET LEADERSHIP; ADDITIONAL HEADWINDS IMPACT Q2 & FUTURE REVENUES

Q2 2024:

Exclusive Accounts Represent

~50%

Of Total IPE Market Volume

- U.S. business continuing to **generate cash**
- Market share **remained stable** through Q2 2024
- Q2 revenues continued to be impacted by U.S. net selling price due to **increasing generic competition**
- **Beginning July 1, we will see significant impact to market share and revenues driven by the loss of a major commercial exclusive account**

AMARIN IS READY TO EXECUTE PLANS TO RETAIN IPE MARKET LEADERSHIP & PROFITABILITY VIA AUTHORIZED GENERIC AT THE OPTIMAL TIME

02 SECOND QUARTER 2024 FINANCIAL RESULTS

Tom Reilly
CFO

REVENUE LOWER DUE TO NET SELLING PRICE OFFSET BY OPERATING EXPENSE MANAGEMENT





Total Net Revenue of $68M in Q2 impacted primarily by U.S. pricing due to generic competition

- U.S. revenue of **$44M**; Decline driven largely by net selling price impact due to generic competition
- Q2 2024 European net product revenues were **$4M**; represents **~84%** net sales growth vs Q1 '24
- Q2 2024 Licensing and royalty revenue of **~$20M** resulting from CVRR indication approval within China

Key operating expense drivers:

- Q2 '24 **$43M** compared to Q2 '23 **$57M**; lower by **$14M**
- **$50M** OpEx reduction as committed in Q3 '23 has been achieved

DESPITE REVENUE SHORTFALL, CASH POSITION REMAINS RESILIENT

PROVIDING STRONG CAPITAL FOUNDATION



Second Quarter 2024

- Cash balance at 6/30/24 of approximately $307M; consistent with Q1 ‘24
- Inventory reduction of approx. **$40M** vs Q2 ‘23
- U.S. and RoW cash generation funding commercial activities in Europe

UPDATE ON STATUS OF PROPOSED SHARE REPURCHASE PROGRAM

01

Company entered into a conditional share repurchase agreement with Cantor Fitzgerald to purchase up to **$50 million** of Amarin's ordinary shares

02

Received **shareholder approval** in April and UK High Court approval in May

03

Company has not commenced any share repurchase to date but will continue to **monitor business and market conditions**

03 CLOSING AND Q&A



Aaron Berg
President & CEO

OUR NEAR-TERM FOCUS: LEVERAGING THE VALUE OF VASCEPA/VAZKEPA FOR PATIENTS GLOBALLY

VASCEPA/VAZKEPA VALUE:

- 10+ YEARS OF SCIENCE & CLINICAL DATA
- GLOBAL UNMET NEED TO REDUCE CV RISK
- UNTAPPED MARKET POTENTIAL IN EUROPE & ROW
- EUROPEAN IP PROTECTION INTO 2039



Evaluate every opportunity

TO MAXIMIZE THE IMPACT OF VASCEPA/VAZKEPA

for millions of patients globally

Q&A

Vascepa®
(icosapent ethyl)

Vazkepa®
(icosapent ethyl)

THANK YOU

AMARIN®